Hellwig, Kerstin http://orcid.org/0000-0003-4467-9011
,
Geissbuehler, Yvonne
Sabidó, Meritxell
Popescu, Catrinel
Adamo, Alessandra
Klinger, Joachim
Ornoy, Asher
Huppke, Peter
Funding for this research was provided by:
Bayer AG
Biogen
Merck KGaA
Novartis Pharma AG
Article History
Received: 14 October 2019
Revised: 11 February 2020
Accepted: 12 February 2020
First Online: 26 February 2020
Compliance with ethical standards
:
: KH has received honoraria and research support from Bayer, Biogen, Teva, Novartis, Sanofi Genzyme, and Merck KGaA. YG is an employee of Novartis Pharma AG. MS is an employee of Merck Healthcare KGaA, Darmstadt, Germany. CP is an employee of Biogen. AA is an employee of Bayer AG. JK is an employee of SynteractHCR GmbH. PH has received honoraria and research support from Bayer, Biogen, Novartis, and Merck KGaA, and is a member of the European Interferon-beta Pregnancy Study Group. AO has nothing to disclose.
: This article is based on a prospective observational collection of data from women exposed to IFN-beta before and/or during pregnancy and their pregnancy outcomes, and does not contain any studies with human participants performed by any of the authors<b>.</b>